Geographic Atrophy Patient Management

Best practices for patient identification, education, and support, as well as treatment decisions and resource management.

By: Carlos Medina, MD

Retinal Physician January 29, 2025

Clinical Report: Geographic Atrophy Patient Management

Overview

This report discusses best practices for managing geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The introduction of new treatments, pegcetacoplan and avacincaptad pegol, necessitates adaptations in patient management strategies to enhance care and support for GA patients.

Background

Geographic atrophy (GA) poses significant challenges in retinal care, particularly as it progresses and impacts patients' quality of life. The recent FDA approvals of pegcetacoplan and avacincaptad pegol for GA treatment have transformed management strategies, emphasizing the need for effective patient identification and education. Understanding the implications of these treatments is crucial for optimizing patient outcomes and resource allocation in clinical settings.

Data Highlights

No numerical data provided in the source material.

Key Findings

Rephrase findings for clarity and ensure they are directly supported by the source material.

Clinical Implications

Clinicians must adapt their office dynamics to accommodate the increased patient load due to new GA treatments. Effective communication and education about treatment processes and potential side effects are essential for patient adherence and satisfaction.

Conclusion

The management of geographic atrophy is evolving with the introduction of new therapies, necessitating a proactive and patient-centered approach to enhance care and quality of life for affected individuals.

PentaVision

Retinal Physician